Welcome to our dedicated page for CYAD news (Ticker: CYAD), a resource for investors and traders seeking the latest updates and insights on CYAD stock.
Celyad Oncology SA (CYAD) is a biotechnology company headquartered in Mont‑Saint‑Guibert, Belgium, with shares admitted to trading on Euronext. Its regulatory news flow provides detailed insight into the company’s strategic focus on managing and licensing its intellectual property portfolio, including proprietary technology platforms, as well as its capital structure and major shareholdings.
News about Celyad Oncology frequently covers decisions that affect its operational profile and financial position. For example, the company has announced the discontinuation of its research and development activities and a significant reduction in its R&D workforce due to limited cash resources, stating that it will concentrate on the management and licensing of its intellectual property portfolio. Other releases describe the divestiture of its research facility’s equipment and office furniture under an asset purchase agreement, which management expects to extend the company’s cash runway.
Investors following CYAD news can also track financing transactions and ownership changes. The company has reported a private placement financing with CFIP CLYD (UK) Limited, an affiliate of Fortress Investment Group, and has issued multiple transparency notifications detailing when this shareholder has crossed voting‑rights thresholds. In addition, Celyad Oncology regularly publishes updates on the total number of shares and voting rights, including the impact of double voting rights on certain registered shares.
This news page is useful for readers who want to monitor regulatory announcements on Celyad Oncology’s strategic decisions, capital increases, asset sales, major shareholdings and voting‑rights structure. By reviewing these updates, users can follow how the company’s focus on intellectual property, its financing arrangements and its ownership profile evolve over time.
Celyad Oncology has transitioned to a new strategic focus aimed at leveraging its proprietary technologies and intellectual property (IP) for CAR T-cell therapies. The company reported an unaudited treasury position of €12.4 million ($13.3 million) as of December 31, 2022. Following the divestment of its manufacturing unit and discontinuation of several clinical programs, Celyad is now prioritizing internal discovery efforts. The interim CEO highlights an innovative approach targeting the limitations of CAR T-cell therapies, with an emphasis on developing dual CAR and multiplexing technologies. However, the firm projects insufficient funds for its operating expenses over the next 12 months.
Celyad Oncology (CYAD) has implemented its Celyad 2.0 business strategy focusing on its intellectual property (IP) and research development. Key aspects include a broad IP estate for allogeneic CAR T-cell therapies, a multiplexing approach, dual CAR development, and B7-H6-targeting immunotherapies. The company will discontinue the CYAD-211 clinical program, primarily due to strategic alignment rather than safety concerns. The strategic shift aims to enhance shareholder value through IP licensing and research advancements. The company anticipates updates on dual CAR and multiplexing programs in Q2 2023.
Celyad Oncology (CYAD) reported a strategic shift in its business model, emphasizing the monetization of its cell therapy intellectual property and advancing R&D. A €6 million asset purchase agreement with Cellistic for its GMP-grade facility bolsters its cash runway. The company has discontinued the development of CYAD-101 due to delays and costs. Updates on the Phase 1 IMMUNICY-1 trial for CYAD-211 are anticipated by the year's end. Financially, as of September 30, 2022, Celyad holds €13.4 million in cash but projects insufficient funds beyond mid-2023 without additional capital.
Celyad Oncology (CYAD) has announced updates on its strategic business model and clinical programs. The company plans to enhance its intellectual property and R&D efforts, especially around its U.S. patents for allogeneic CAR T therapies. Notably, it has decided to discontinue the development of CYAD-101 for metastatic colorectal cancer due to financial and medical reviews, though no new safety issues were reported. In contrast, CYAD-211 continues in the Phase 1 trial, showing promising results in managing graft-versus-host disease. Clinical updates are expected by year-end.
Celyad Oncology has announced the sale of its Good Manufacturing Practice (GMP) cell therapy manufacturing operations to Cellistic for €6 million. The facility, located in Mont-Saint-Guibert, Belgium, comes with an experienced team of over 30 personnel. The transaction aims to streamline Celyad's focus on allogeneic therapies while leveraging Cellistic's expertise in iPSC-based cell therapies. The deal is anticipated to close in Q4 2022, providing Celyad with resources to continue its clinical programs until 2024.
Celyad Oncology announced ongoing enrollment in its Phase 1 dose-escalation trial for CYAD-211, targeting relapsed/refractory multiple myeloma. The FDA lifted the hold on CYAD-101 for metastatic colorectal cancer. The company reported a net loss of €14.1 million for H1 2022, an improvement from €14.9 million in H1 2021. Cash reserves stand at €14.4 million. Research and development expenses rose to €10.5 million due to increased IP costs. Celyad aims to enhance partnerships leveraging its extensive CAR T technology IP portfolio.
Celyad Oncology (CYAD) announced the FDA has lifted the clinical hold on its CYAD-101-002 (KEYNOTE-B79) Phase 1b trial, enabling the continuation of its investigation into allogeneic NKG2D CAR T cell therapy combined with KEYTRUDA for refractory metastatic colorectal cancer. The trial had been paused due to safety concerns following reports of fatalities. Celyad remains optimistic about the potential of CYAD-101 and its proprietary TIM technology.
Celyad Oncology SA (Euronext & Nasdaq: CYAD) announced plans to report its first half 2022 financial and operating results on August 5, 2022. Following this release, management will host a conference call at 2 p.m. CEST to discuss the results and updates on recent progress and milestones.
The company is focused on CAR T therapies for cancer and has a pipeline of candidates for treating hematological malignancies and solid tumors. Detailed insights on its financial condition and ongoing trials, including the CYAD-101-002 trial, will be provided during the call.
Celyad Oncology SA (NASDAQ:CYAD) announced the appointment of Hilde Windels as Chairwoman of the Board of Directors, effective immediately. Windels has been on the board since May 2018 and has extensive experience in the life sciences sector. She replaces Michel Lussier, who becomes the Interim Chief Executive Officer following the resignation of Filippo Petti. Petti will assist during the transition until July 31, 2022. The company's strategy focuses on developing innovative CAR T therapies for cancer.
Celyad Oncology SA (Euronext & Nasdaq: CYAD) announced that as of May 25, 2022, 350 registered shares will benefit from double voting rights. This change increases the total number of voting rights to 24,962,331. The company disclosed this in compliance with Belgian regulations regarding major shareholdings. Key figures include a total share capital of €78,584,224.33, with 20,225,581 shares having single voting rights and 2,368,375 shares having double voting rights.